The product designated Gegen Lianbai Powder Veterinary Grade API is supplied as a multi-component botanical active pharmaceutical ingredient intended solely for further manufacture of veterinary medicinal dosage forms including tablets, injections, capsules, powders, granules, premixes, and solutions. The veterinary API designation separates this material from feed-grade or crude botanical powders through active-substance GMP controls described in ICH Q7, batch traceability to source lots, defined marker content, and release testing for microbial, heavy metal, residual solvent, and foreign matter attributes. The powder is normally presented as a milled or micronized botanical material with controlled sieve residue and loss on drying; actual lot values appear on the certificate of analysis and active-substance master file rather than in a single pharmacopoeial monograph. Model designation is site-specific and generally appears as an internal grade or drug master file reference code, not as a compendial model number. Published data for this named product is limited; the technical profile below therefore draws on the behaviour of comparable non-sterile botanical API powders under production conditions.

Because multi-constituent botanical APIs are released on marker assay and chromatographic fingerprint rather than a single purity value, the same lot may be suitable for oral granulation or premix blending but fail an injectable solution’s endotoxin or particulate requirements. In tablet and capsule manufacture the powder is the active input to dry or wet granulation; in powders and premixes it is dispersed by geometric dilution; in solutions it is dissolved or suspended and clarified; in injectables it is dissolved, filtered, and processed aseptically. Route-specific specification is therefore mandatory before any dosage-form manufacture.

What Limits a Botanical API Across Injection, Tablet, and Premix Manufacture?

The critical limitation is the gap between non-sterile powder bioburden and the acceptance criteria of the intended route. Non-sterile oral tablets and premixes can generally accept total aerobic microbial counts up to 10⁴ CFU/g and yeast/mould counts up to 10² CFU/g under Ph. Eur. 2.6.12 or USP <61>, while injectable solutions impose bacterial endotoxin and particulate limits that require additional purification, sterilizing-grade filtration, or aseptic processing. A powder lot passing oral specifications cannot be used for injection without further endotoxin control. Tablets and capsules require the API to maintain a particle size distribution compatible with high-speed die fill; premixes require homogeneous distribution at inclusion rates below 1.0% in a carrier. The same powder lot must therefore be evaluated against the process, not against a universal API specification.

Dry blending of this API class at production scale is limited by segregation under forced-flow conditions. When the particle size distribution spans more than 200 µm between D10 and D90, vibration from a rotary tablet press can stratify the blend by particle size and bulk density. Cone mills fitted with 0.045 inch screens and fluid-bed granulators operated at inlet air temperatures below 60 °C are commonly used to reduce oversized particles while preserving heat-sensitive marker constituents. Direct compression formulations containing this botanical API generally require a D90 of 150 µm or less and a bulk density above 0.45 g/cm³ to maintain die fill uniformity at press speeds above 50,000 tablets/h. At relative humidity above 60%, surface moisture adsorption and caking occur in uncoated botanical powders; sealed storage with desiccant is standard. These values are typical for non-sterile botanical API powders, not lot-specific guarantees for the named product.

Specification Grid and Test Methodology for Non-Sterile Botanical Veterinary API

For a botanical API of this class, the release specification is typically built around the parameters shown below. The listed values are representative industrial controls; the manufacturer’s drug master file may adopt stricter or different limits depending on extraction route and intended dosage form.

Residual solvent limits are aligned with ICH Q3C and VICH GL18 for Class 3 solvents at 50 mg/day; if Class 2 solvents are used in extraction, specific limits must be listed in the active-substance master file. Bacterial endotoxins are not a routine release parameter for oral, premix, or granule applications; they become critical for injections and should be included in the route-specific specification if parenteral use is claimed.

Extraction and drying history also influence downstream behaviour. Spray-dried powders of this class typically exhibit spherical particle morphology, lower bulk density, and residual moisture below 5.0%, whereas vacuum-dried extracts may require more aggressive milling and can be more hygroscopic. These differences control whether the API can be used as received in direct compression or must be granulated. Spray-dried material often has better flow but may retain amorphous constituents that recrystallize under humid storage; vacuum-dried material may have fewer amorphous components but a wider particle size distribution unless milled under controlled conditions.

When a Multi-Constituent API Replaces Synthetic Actives in Veterinary Dosage Forms

Substituting a botanical API for a synthetic single-molecule active is not a drop-in because the botanical powder carries additional non-active constituents that affect granulation, flow, stability, and analytical specificity. The following table summarises the main differences among this product class, a synthetic veterinary API, and a feed-grade botanical powder.

Compared with human-grade botanical extracts, a veterinary API must also address species-specific residue depletion and withdrawal periods. An extract that meets human dietary supplement limits may still be unacceptable for food-producing species if the marker or co-extracted constituent lacks a maximum residue limit or if the analytical method cannot measure depletion in edible tissues. Therefore, use in veterinary dosage forms requires data beyond a human-grade certificate of analysis.

On production-scale injectable lines, a non-sterile botanical API powder introduces colloidal polysaccharides, tannins, and particulate matter that reduce throughput of 0.2 µm sterilizing-grade filters. Prefiltration through depth filters or 0.45 µm membranes is commonly required; filter capacity for comparable botanical extracts can be 20–40% lower than for synthetic solutions because of membrane fouling. Terminal sterilization at 121 °C may be unsuitable if marker compounds are thermally labile; therefore, aseptic filtration is often the limiting unit operation. Published data for this specific API is limited; filterability and thermal stability must be confirmed on each lot before parenteral manufacture.

Wet granulation is used for this API class when direct compression fails due to poor compactibility. A binder solution containing 3–5% povidone or pregelatinized starch is typical; the binder is added slowly because natural gums in the powder may hydrate prematurely and produce over-wet granules. For tablets containing more than 30% botanical API, microcrystalline cellulose at 20–40% and crospovidone at 2–5% are frequently required to achieve hardness between 40 N and 80 N and friability below 1.0%. Direct compression may be used only if the API and excipients maintain a Carr index below 25 and the blend passes sieve segregation testing at the target press speed. Drying of wet granules in a fluid-bed at inlet temperatures below 60 °C to a final loss on drying of 2.0–3.0% is a common process window for botanical extracts.

For hard capsules, a D90 of 150 µm or less and bulk density between 0.45 g/cm³ and 0.65 g/cm³ are generally required to avoid short fills on tamping-pin machines. For powders and medicated premixes, geometric dilution with lactose or corncob carrier is used until the coefficient of variation at a 10 g sample size is below 5.0%; simple scoop blending is insufficient at inclusion rates below 1.0%. For oral solutions, the API is dispersed in a buffered vehicle, and undissolved cellulosic or pectinaceous material is removed by clarification before packaging to prevent sedimentation and nozzle blockage during drench administration. pH adjustment may be required; acidic vehicles below pH 4.0 can gel pectin-like constituents and increase viscosity.

In medicated feed production, carryover is controlled by flush cleaning and residue verification. Botanical API fractions that become sticky under mixer heat or friction may adhere to ribbon mixers and transfer to subsequent batches. Residue limits are set according to the lowest active concentration that can be detected in feed; if analytical detection is poor, a marker assay should be extended to feed matrix testing. Species-specific withdrawal periods are governed by the marketing authorization; the API supplier does not define the withdrawal period, but batch consistency and marker assay support the residue depletion data required for veterinary medicinal products.

Analytical release for this product class is more demanding than for a synthetic single-molecule API because matrix effects from co-extracted constituents can suppress or enhance marker response. High-performance liquid chromatography with marker assay and high-performance thin-layer chromatography fingerprint are commonly used; when no pharmacopoeial monograph exists, method validation should follow ICH Q2 or VICH GL1 and include specificity against related botanical species. Batch-to-batch marker content for botanical extracts can vary by ±10% or more if harvest season and extraction conditions are not controlled; therefore, blending of multiple extract lots is often necessary to meet a 90.0–110.0% marker claim.

Route-specific process validation remains the controlling requirement. A certificate of analysis demonstrating compliance with non-sterile oral limits does not qualify a lot for injectable use, and a particle size specification suitable for tablets may not be adequate for low-inclusion premixes. Scale-up trials should include blend uniformity sampling, filter capacity testing for injectable formulations, and stability studies under VICH GL3 or VICH GL5 conditions rather than relying on general botanical powder profiles. Without a valid pharmacopoeial monograph for this named product, batch selection is driven by marker assay reproducibility, chromatographic fingerprint similarity, and process-specific tests such as reconstitution clarity, compressibility, and homogeneity.